RDR Alert®

Study suggests a link between Lynch syndrome (LS) and more cancer types than previously thought.

The first patient has been dosed in the phase 2 expansion portion of its monotherapy trial of eFT508 for the treatment of relapsed, refractory non-germinal center B cell (non-GCB) diffuse large B cell lymphoma (DLBCL).

Phase 1/2a clinical trial (NCT02253212) data on ultrasound-induced blood-brain barrier (BBB) opening for brain disorders like recurrent glioblastoma.

Iobenguane I 131 (AZEDRA) has been shown to be effective in patients with malignant, recurrent, or unresectable pheochromocytoma and paraganglioma (pheo/para).

The use of the maintenance regimen increased both 5-year disease-free survival (DFS) and 5-year overall survival (OS) in rhabdomyosarcoma.

FDA accepts Genentech's supplemental Biologics License Application (sBLA) and grants Priority Review to its product, emicizumab-kxwh (HEMLIBRA), for the treatment of hemophilia A without factor VIII inhibitors in both children and adults.

Pauline Funchain MD, explains her research which focuses on assessing possible underlying genetic and familial factors in melanomas.

Radhakrishnan Ramchandren MD, highlights the recent US Food and Drug Administration’s (FDA) approval and advantages of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for advanced stage, classic Hodgkin lymphoma.

The phase 3 iNNOVATE trial finds ibrutinib in combination with rituximab to be safe and effective in relapsed/refractory and treatment-näive patients with Waldenström’s macroglobulinemia.

Researchers present promising phase 2 data regarding tazemetostat for malignant mesothelioma, the first reported clinical data of an EZH2 inhibitor in these patients.

Manuel Litchman, MD, President and CEO of Mustang Bio Inc, highlights the advantages of using CAR-T therapies as treatments for rare cancers.

E. Anders Kolb, MD, Director of Nemours Center for Cancer and Blood Disorders at Nemours/Alfred I. duPont Hospital for Children, explains the importance of teaching resiliency as an educational tool and addressing the psychosocial burdens placed on patients in pediatric oncology.

Researchers release updated data from the phase 3 ALEX trial comparing alectinib with crizotinib as first-line treatment against ALK-positive non-small cell lung cancer.

Manmeet Ahluwalia, MD, Head of Operations in the Brain Tumor Center at Cleveland Clinic, explains what a team approach should look like when treating brain tumors and other rare cancers.

Researchers find that the use of PET scans at baseline and after induction therapy can help them tailor chemotherapy regimens in esophageal cancer patients, increasing survival.

Owen A. O’Connor, MD, PhD, Director of Center for Lymphoid Malignancies at Columbia University, emphasizes the importance of sharing experiences among physicians and researchers in the rare diseases like peripheral T-cell lymphomas.

Manmeet Ahluwalia, MD, Head of Operations in the Brain Tumor Center at Cleveland Clinic, discusses the importance of team approaches when treating brain tumors and other rare cancers.

Researchers report positive results for phase 1 trial of ivosidenib in patients with IDH1+ acute myeloid leukemia.

Results of a recent study demonstrate that treatment at a specialized cancer center is associated with better leukemia-specific survival in children, adolescents, and young adults.

A new phase 3 clinical trial boasts highest survival rates of these T-cell malignancies.

First-in-man phase 1 trial meets its primary endpoints by demonstrating safety and immunogenicity of a mutation-specific IDH1R132H peptide vaccine.

To date, OPTIMISMM is the only phase 3 study in early RRMM to report a significantly and clinically meaningful PFS improvement in LEN-exposed patients.

Prospective genomics can inform subsequent clinical trial analysis aiming at matching outcome with tumor genotyping.

Express Scripts announces a new Rare Conditions Care Value program for rare disease patients with introduction support service of Second Opinion in partnership with PinnacleCare.

Saby George, MD, FACP, and Dena Battle, president of nonprofit patient advocacy group, KCCure, discussapproval of Opdivo (nivolumab) and Yervoy (ipilimumab) therpay combination for kidney cancer.